Shared Resource Management

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Linked publications, trials & patents

Abstract

PROJECT SUMMARY Under the leadership of the Associate Director, Marion Dorer, PhD, MBA and Deputy Associate Director, Gordon Roble, DVM, MBA, the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium (Consortium) Shared Resources (SR) consists of eleven established SRs, supported by a centralized SR Management team. The SRs include Biostatistics (BSR), Cellular Imaging & Electron Microscopy (CI&EMSR), Collaborative Data Services (CDSSR), Comparative Medicine (CMSR), Genomics & Bioinformatics (G&BSR), Immune Monitoring & Flow Cytometry (IM&FCSR), Prevention Center (PCSR), Proteomics & Metabolomics (P&MSR), Research Pathology (RPSR), Therapeutic Manufacturing (TMSR), and Translational Bioimaging (TBICSR). The developing Preclinical Modeling (PCMSR) will be integrated with CMSR. Each resource is led by a highly qualified director(s) with a dedicated Faculty Advisory Committee (FAC). The Shared Resources Oversight Committee (SROC) evaluates information from SR leaders, expert staff, user surveys, FACs and the strategic plan to drive decisions benefiting all users. The SROC reports to the External Advisory Board (EAB) and Cancer Consortium Executive Committee (EC). In the last grant cycle, the Consortium added numerous service lines and made capital equipment investments ($20.8M), capital facilities modifications ($12.9M), and operating investments ($40.3M), totaling $77.1M, in support of strategic plans to lead in scientific discovery and research innovation. Major equipment additions include but are not limited to PacBio Sequell IIe, Biomek i7 Liquid Handler, Nanostring GeoMx DSP and CosMX SMI, two Illumina NextSeq 2000, Andor Dragonfly Spinning Disk, Nikon Ring TIRF, Glacios Cryo-TEM, Vevo F2 preclinical ultrasound, Quantum GX2 microCT, three IncuCyte, specialized mouse housing systems, and multiple cell sorters and analyzers. Notable facility upgrades were undertaken for cryo-EM (CI&EMSR) and a 40% increase in space and instrumentation for flow cytometry (IM&FCSR). SR Directors were awarded three successful NIH S10 grants for TBICSR and P&MSR including the addition of a new 7T preclinical MRI system to enhance capabilities for brain and other cancer-related imaging in rodents and a Orbitrap Eclipse mass spectrometer for proteome quantification and protein characterization. SRs contributed to 839 peer-reviewed publications in the past cycle, including 31% with an impact factor (IF) ≥ 10 and 11% with IF ≥ 20. 285 of the publications were supported by more than one SR. Additionally, 269 of these publications were co-authored by SR staff in collaboration with members from all research programs. Looking forward in support of our members, the Consortium strategic plan has resulted in two new developing SRs. The Recruitment & Retention Resource (R&RSR) will improve engagement and recruitment of participants in clinical research. The Rapid Autopsy SR (RASR) will address the needs of translational researchers for fresh and frozen biospecimens.